Compare Incyte Corporation (INCY) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Remitly Global Inc — how do they compare? Incyte Corporation trades at $112.75 (market cap $22.85B), while Remitly Global Inc trades at $23.5 (market cap $4.98B). The key difference: Incyte Corporation is far larger — about 4.6× Remitly Global Inc's market cap, and Remitly Global Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Remitly Global Inc for 53 Days on average.
| INCY | RELY | |
|---|---|---|
Market Cap | $22.85B | $4.98B |
Volume | 1,927,029 | 3,501,150 |
Sector | Health | Technology |
52-Week High | $129.93 | $26.92 |
52-Week Low | $83.80 | $12.20 |
Typical Hold Time | 33 Days | 53 Days |
Enterprise Value | $18.35B | $4.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
RELY trades at $22.93, down 1.16% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. Revenue has grown from $654M in 2022 to $1.64B in 2025, with net income turning positive at $67.93M. The company recently announced a partnership with Etsy and reported Q2 2026 revenue growth of 20% to $495M, with active customers surpassing 10 million.
The outlook is positive, supported by robust earnings beats, expanding margins, and a consensus analyst price target of $30.50 implying significant upside. Key risks include reliance on continued customer growth, competitive pressures in digital payments, and market volatility. Institutional ownership trends and insider sales warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
